Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (ALNY) said Monday that they have initiated a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference or RNAi therapeutic for the treatment of chronic hepatitis B virus or HBV infection.
from RTT - Biotech https://ift.tt/2E1l1a2
via IFTTT
No comments:
Post a Comment